• 1
    Jaffe ES, Harris NL, Chan JKC, Stein H, Vardiman JW. Proposed World Health Organization classification of neoplastic disease of the hematopoietic and lymphoid tissues. Am J Surg Pathol. 1997; 21: 114121.
  • 2
    Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization: classification of tumours. Tumours of haematopoietic and lymhoid tissue. Lyon: IARC Press, 2001: 135137.
  • 3
    Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. Blood. 2000; 96: 410419.
  • 4
    Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003; 101: 24892495.
  • 5
    Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma. 2002; 3: 4147.
  • 6
    Chacón JI, Mollejo M, Muñoz E, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood. 2002; 100: 16481654.
  • 7
    Nathwani BN, Anderson JR, Armitage JO, et al. Marginal zone B-cell lymphoma: a clinical comparison of nodal and mucosa-associated lymphoid tissue types. J Clin Oncol. 1999; 17: 24862492.
  • 8
    Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000; 95: 19501956.
  • 9
    Franco V, Florena AM, Iannitto E. Splenic marginal zone lymphoma. Blood. 2003; 101: 24642472.
  • 10
    Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol. 2003; 4: 95103.
  • 11
    Matutes E, Morilla R, Owusu-Ankomah K, Houlihan A, Catovsky D. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood. 1994; 83: 15581562.
  • 12
    Isaacson PG, Matutes E, Burke M, Catovsky D. The histopathology of splenic lymphoma with villous lymphocytes. Blood. 1994; 84: 38283834.
  • 13
    Zuckerman E, Zuckerman T, Levine A, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med. 1997; 127: 423428.
  • 14
    Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002; 347: 8994.
  • 15
    Shi SR, Itzkowits SH, Kim YS. A comparison of three immunoperoxidase techniques for antigen detection in colorectal carcinoma tissues. J Histochem Cytochem. 1988; 36: 317322.
  • 16
    Rosso R, Neiman RS, Paulli M, et al. Splenic marginal zone cell lymphoma: report of an indolent variant without massive splenomegaly presumably representing an early phase of the disease. Hum Pathol. 1995; 26: 3946.
  • 17
    Campello C, Poli A, Dal MG, Besozzi-Valentini F. Seroprevalence, viremia and genotype distribution of hepatitis C virus: a community-based population study in northern Italy. Infection. 2002; 30: 712.
  • 18
    Marasca R, Vaccari P, Luppi M, Zucchini P, Castelli I, Barozzi P, Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol. 2001; 159: 253261.
  • 19
    Franco V, Florena AM, Stella M, et al. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer. 2001; 91: 294301.